Point Mutation Models

Precision single-nucleotide modifications to replicate human disease variants. We offer two primary strategic approaches for functional and clinical research.

Conventional PM

Standard germline modifications for systemic variant study.

Conditional PM

Cre-LoxP regulated mutations for tissue-specific induction.

Conventional Point Mutation

Conventional PM Strategy

Hypertrophic Cardiomyopathy (HCM)

Utilizing Cas9 technology, we constructed a model carrying the H530R PRKAG2 mutation. These mice accurately exhibit human clinical symptoms, including myocardial hypertrophy and glycogen storage.

Conditional Point Mutation

By combining human disease candidate mutations with the Cre-LoxP system, mutations are introduced into homologous mouse gene positions for sophisticated, tissue-specific pathological analysis.

Conditional PM Strategy A
Conditional PM Strategy B

Spontaneous Lung Cancer Model

A bronchiole-specific model achieved by crossing Kras-(LSL-G12D) mice with Scgb1a1-CreERT2 mice. This allows for the study of spontaneous oncogenesis in a controlled, tissue-specific environment.

Lung Cancer Model Strategy